Pat Furlong

Pat Furlong

Company: Parent Project Muscular Dystrophy

Job title: Founding President & Chief Executive Officer


With three decades of expertise in translational medicine Pat Furlong, president and CEO of PPMD, has led ground-breaking research and cultivated meaningful patient engagement strategies, bridging the gap between scientific innovation and patient well-being.


Panel Discussion: Reaching, Enrolling, and Retaining Participants in Rare Disease Gene Therapy Trials 2:00 pm

Multi-stakeholder discussion of friction points in the development lifecycle and how to overcome them: what have we tried, what has been successful and under what circumstances Dissection of real-world examples over time and across different patient communities Analysis of recent trends and impacts of continuing advancesRead more

day: Clinical - PM

Panel Discussion: Evolving the Patient Engagement Paradigm in Rare Disease 4:00 pm

Outlining how all stakeholders stand to benefit from patient groups being involved throughout the drug development path How can drug developers ensure that the patient voice is never lost throughout the development process? Where in the drug development pathway are their further opportunities for drug developers to engage rare disease patient groups? Stories of successful…Read more

day: Day Two PM

Outlining Success Stories in Value Demonstration to Private Insurers 9:30 am

The Duchenne Muscular Dystrophy Story: Driving forward access of an approved gene therapy by working with patients and insurers Leveraging publications from healthcare professionals around value-based assessments and the therapeutic need Addressing the need for consistent messaging between stakeholders in one disease communityRead more

day: Day Two AM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.